BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 8273369)

  • 1. [Interferon therapy in malignant melanoma].
    Kokoschka EM; Micksche M
    Wien Med Wochenschr; 1993; 143(16-17):441-2. PubMed ID: 8273369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant melanoma.
    Califano J; Nance M
    Facial Plast Surg Clin North Am; 2009 Aug; 17(3):337-48. PubMed ID: 19698915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
    Kirkwood JM; Tarhini AA
    Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Significant survival advantage in 96 treated patients in comparison with 288 untreated symptomatic controls].
    Beiteke U; Ruppert P; Garbe C; Oxenfarth R; Kastl I; Türker T; Tronnier H; Frosch PJ
    Hautarzt; 1993 Jun; 44(6):365-71. PubMed ID: 8335459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
    McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
    Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adjuvant and palliative therapy of melanoma. Current status].
    Tilgen W
    Chirurg; 1994 Mar; 65(3):153-63. PubMed ID: 7514966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tolerance and feasibility of adjuvant treatment of stage II malignant melanoma with high-dose interferon-alpha].
    Bédane C; Le Brun V; Boulinguez S; Berdah JF; Bouyssou ML; Delpuget N; Bernard P; Tubiana-Mathieu N; Bonnetblanc JM
    Ann Dermatol Venereol; 1999 Feb; 126(2):142-6. PubMed ID: 10352829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Consensus conference. Follow-up of patients surgically treated for stage I melanoma].
    Ann Dermatol Venereol; 1995; 122(5):250-8. PubMed ID: 8572461
    [No Abstract]   [Full Text] [Related]  

  • 9. [Combined and complex treatment of patients with II-stage malignant skin melanoma using hyperthermia].
    Zhavrid EA; Fradkin SZ; Bezruchko VI; Firmanchuk AV; Proleskovskiĭ AK
    Vopr Onkol; 1986; 32(3):52-7. PubMed ID: 3962258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of metastasized malignant melanoma].
    Kamanabrou D
    Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comment on the contribution by U. Beiteke et al. Adjuvant therapy of primary malignant melanoma with natural human interferon-beta. Second comment].
    Gefeller O; Kleeberg U; Kölmel KF
    Hautarzt; 1994 Mar; 45(3):191-2; author reply 193-4. PubMed ID: 8175352
    [No Abstract]   [Full Text] [Related]  

  • 12. [To outwit melanoma with its own tricks].
    Bischoff A
    MMW Fortschr Med; 2003 Apr; 145(15):4-6, 8, 10. PubMed ID: 15104255
    [No Abstract]   [Full Text] [Related]  

  • 13. [Melanoma].
    Saida T
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1386-91. PubMed ID: 17033225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidisciplinary treatment of primary melanoma.
    Yao K; Balch G; Winchester DJ
    Surg Clin North Am; 2009 Feb; 89(1):267-81, xi. PubMed ID: 19186240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence of cutaneous malignant melanoma after more than 20 years.
    Bredgaard R; Lock-Andersen J
    J Plast Surg Hand Surg; 2011 Apr; 45(2):113-6. PubMed ID: 21504283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
    Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
    J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant therapy of malignant melanoma].
    Franke W; Neumann NJ; Ruzicka T; Schulte KW
    Praxis (Bern 1994); 2001 Feb; 90(8):301-6. PubMed ID: 11256332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The adjuvant therapy of malignant melanoma].
    Hauschild A; Sterry W
    Dtsch Med Wochenschr; 1992 Feb; 117(8):303-6. PubMed ID: 1537268
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.